INCREASED EXPRESSION OF PENTRAXIN 3 IN
PLACENTAL TISSUES FROM PATIENTS WITH
UNEXPLAINED RECURRENT PREGNANCY LOSS
Zeybek S1,*, Tepeli E2, Cetin GO3, Caner V3, Senol H4, Yildirim B2, Bagci G3
*Corresponding Author: Selcan Zeybek, M.D., Department of Medical Genetics, Erzurum Regional
Training and Research Hospital, Cat Volu Street, 25070, Erzurum, Turkey. Tel.: +90-506-399-2644.
Fax: +90-442-232-5025. E-mail: selcankesan@yahoo.com
page: 21
download article in pdf format
|
|
Abstract
Pentraxin 3 (PTX3), a prototypical member of the
long pentraxin subfamily, is a evolutionarily conserved
multimeric pattern recognition receptor involved in the
humoral component of the innate immune system. Pentraxin
3 is released when tissue is stressed or damaged,
and interacts with many different ligands. Pentraxin 3 exerts
a pivotal role both as a regulator and as an indicator
of inflammatory response in the pathogenesis of many
diseases such as sepsis, vasculitis and preeclampsia. Uncontrolled
inflammatory response is considered a major
cause of unexplained recurrent pregnancy loss (URPL). We
determined the PTX3 messenger ribonucleic acid (mRNA)
and protein expression levels in placental tissues from 50
women with URPL, and made comparison with those in
50 age-matched control subjects. In quantitative real-time
polymerase chain reaction (qRT-PCR) and immunohistochemistry
analyses, PTX3 mRNA and protein levels,
respectively, were significantly increased in URPL patients
compared with their respective controls (p = 0.0001). Although
no significant correlations were identified between
PTX3 expression levels and clinical parameters such as
maternal age, numbers of previous pregnancy losses, and
gestational age at miscarriage, PTX3 mRNA expression
was significantly higher in patients with no live births
than in women with previous live births (p = 0.0001). Our
study suggests that tissue-specific expression of PTX3 is
associated with URPL. Further larger studies are required
to determine whether PTX3 expression can be used as a
biomarker to manage URPL in routine clinical practice.
|
|
|
|
 |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
|
